TAB 
SUMMARY OF NYVAC APPENDICES 
A 
"The Complete DNA Sequence of Vaccinia Virus", Goebel, et al.. 
Virology, 179:247-266 (1990). 
B 
"NYVAC: A Highly Attenuated Strain of Vaccinia Virus", Tartaglia et al., 
Virology, 188:217-232 (1992). This paper presents data on the identity, 
safety, and potency of NYVAC, and compares it to other strains of 
vaccinia and the canarypox vector ALVAC (CPpp). 
C 
"Highly attenuated Poxvirus Vectors in AIDS Vaccine Development", Cox 
et al Submitted for publication. This paper presents data showing the 
ability of NYVAC-based constructs to express extrinsic immunogens and 
elicit protective immune responses. 
D 
"Vaccinia Virus Host Range Genes", Perkus, et al.. Virology, 179:276-286 
(1990). This article discusses the diminished or eliminated ability of 
NYVAC to replicate in tissue culture cells derived form certain species, 
such as swine and humans. 
E 
This study compares replication of two NYVAC-based recombinants on 
eight mammalian cell lines, including human MRC-5. 
F 
This study compares the replicative ability of three vaccinia strains 
(NYVAC, WR L-variant, and VC-2) by analyzing their dissemination to 
and accumulation in mouse ovaries, lungs, livers, and spleen. 
G 
Report on the virulence of NYVAC-RG (vP879) in rabbits inoculated by 
the intracerebral route (PMs&v report #LV075CRT). 
H 
Letter from Dr. Fred Quimby, Director, Center for Research Animal 
Resources, Cornell University; and draft report from Dr. Dorothy Holmes, 
both describing the absence of any detectable local or systemic reaction in 
twelve horses vaccinated with NYVAC-based recombinants. 
I 
Report presenting serology data which addresses the issue of transmission 
of recombinants from vaccinated swine to non- vaccinates. 
J 
"Vaccination of Pigs Against Pseudorabies with Highly Attenuated Vaccinia 
(NYVAC) Recombinant Viruses", Brockmeier, et al., submitted for 
publication. This paper discusses the safety, potency, and efficacy of a 
NYVAC-based JEV vaccine. 
K 
Letter from Dr. Genoveffa Franchini, Head of the Vaccine Unit, 
Laboratory of Tumor Cell Biology, NIH, NCI. 
Recombinant DNA Research, Volume 18 
[173] 
